Lyterian Therapeutics
Laura Clarke has a strong background in scientific research and has worked in various roles within the pharmaceutical and academic sectors. Laura began their career as an Industrial Placement Student at Novartis Institutes for BioMedical Research (NIBR) in 2005. Laura then pursued their education and obtained a Neuroscience Ph.D from UCL, where they were a student from 2007 to 2012.
After completing their Ph.D, Laura joined Stanford University as a Postdoctoral Scholar in 2012 and worked there until 2019. During this time, they gained valuable experience in their field. In 2019, they transitioned to Denali Therapeutics, where they held the position of Project team leader and Scientist. Their work at Denali lasted until 2023, during which they demonstrated strong leadership skills and contributed to various projects.
Currently, Laura is employed as a Principal Scientist at Lyterian Therapeutics since June 2023. With their extensive experience and expertise, they are well-positioned to contribute to the scientific advancements in their field.
Laura Clarke completed their Bachelor of Science in Pharmacology at The University of Manchester in 2007. Subsequently, they pursued a Doctor of Philosophy in Neuroscience at UCL starting in 2012. There is no information available regarding their education at Stanford University.
This person is not in the org chart
This person is not in any offices
Lyterian Therapeutics
1 followers
Lyterian Therapeutics derives its name from the Greek word λυτήριος or lutḗrios, that defines the termination, healing, or end of disease. Disease resolution is coordinated by endogenous and exogenous agents that recruit cells and other effectors to the site of injury. We are inspired to learn from the logic that orchestrates homeostatic equilibria and fosters healing in response to disease. At Lyterian Therapeutics, we are committed to developing medicines for patients in need by co-opting physiologically relevant protein homeostatic mechanisms to regulate genetically validated targets.
Employees
1-10